National Bank of Canada’s Moderna MRNA Stock Holding History

National Bank of Canada’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.75M	Buy	+1,250	New	+$64.7K	0.01%	780
2022 Q4	–	Sell	-2	Closed	-$17K	–	2854
2022 Q3	$17K	Hold	2	–	–	﹤0.01%	2057
2022 Q2	$22K	Hold	2	–	–	﹤0.01%	2052
2022 Q1	$28K	Hold	2	–	–	﹤0.01%	2067
2021 Q4	$34K	Buy	+2	New	+$585	﹤0.01%	1998

Other funds holding MRNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

National Bank of Canada's MRNA Position: Q2 2026 in Review

National Bank of Canada reduced its Moderna (MRNA) stake by 22% in Q2 2026, selling an estimated $20.3M and leaving 1,424,802 shares worth $99.8M. The position accounts for 0.07% of the portfolio, ranked #208.

National Bank of Canada first reported a position in MRNA in Q4 2021 and has held it in 19 quarters since. 503 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

National Bank of Canada held 1,424,802 shares of Moderna worth $99.8M as of Q2 2026.
National Bank of Canada sold 392,199 Moderna shares in Q2 2026, an estimated $20.3M.
Moderna made up 0.07% of National Bank of Canada's portfolio in Q2 2026, its #208 holding.
National Bank of Canada first reported a position in Moderna in Q4 2021 and has held it in 19 quarters since.
503 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.